期刊文献+

心力衰竭的能量代谢重构及其治疗 被引量:32

暂未订购
导出
摘要 在心力衰竭发生发展的过程中,肥厚和衰竭的心肌往往发生了能量和底物代谢的改变,并直接或间接地促进了心肌重构的发展,即心肌的能量"代谢重构"。针对这一靶点,通过哌克昔林、曲美他嗪、左卡尼汀等药物抑制游离脂肪酸的摄取、β-氧化或直接促进葡萄糖代谢,均可能进一步优化心肌的能量底物代谢,更好地保存或改善心肌功能,延缓心力衰竭的进展。
出处 《国际心血管病杂志》 2012年第2期65-67,共3页 International Journal of Cardiovascular Disease
基金 国家自然科学基金(30470457)
  • 相关文献

参考文献21

  • 1van Bilsen M, Smeets PJ, Gilde AJ, et al. Metabolic remodelling of the failing heart: the cardiac burn out syndrome? [J]. Cardiovasc Res,2004,61 (2) :218-226.
  • 2Tuunanen H, Knuuti J. Metabolic remodelling in human heart failure[J]. Cardiovasc Res,2011,90(2) :251 -257.
  • 3Tuunanen H, Engblom E, Naum A, et al. Free fatty acid depletion acutely decreases cardiac work and efficiency in cardiomyopathic heart failure [J]. Circulation, 2006, 114 (20) :2130-2137.
  • 4Halbirk M, Norrelund H, Moller N, et al. Suppression of circulating free fatty acids with acipimox in chronic heart failure patients changes whole body metabolism but does not affect cardiac function[J]. Am J Physiol Heart Circ Physiol, 2010,299(4) :H1220- 1225.
  • 5Abozguia K, Elliott P, McKenna W, et al. Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy [J]. Circulation,2010,122(16) : 1562- 1569.
  • 6Rupp H, Zarain-Herzberg A, Maisch B. The use of partial fatty acid oxidation inhibitors for metabolic therapy of angina pectoris and heart failure[J]. Herz, 2002,27(7) :621-636.
  • 7Bristow M. Etomoxir: a new approach to treatment of chronic heart failure[J]. Lancet,2000,356(9242) :1621-1622.
  • 8Holubarseh CJ, Rohrbach M, Karrasch M, et al. A double- blind randomized multicentre clinical trial to evaluate the efficacy and safety of two doses of etomoxir in comparison with placebo in patients with moderate congestive heart failure: the ERGO (etomoxir for the recovery of glucose oxidation) study [J]. Clin Sci (Lond), 2007, 113 (4): 205-212.
  • 9Fragasso G, Palloshi A, Puccetti P, et al. A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure [J]. J Am Coll Cardiol, 2006,48 (5) : 992 -998.
  • 10Tuunanen H, Engblom E, Nauru A, et al. Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy[J]. Circulation, 2008, 118 (12) :1250 -1258.

二级参考文献13

  • 1荆志成.六分钟步行距离试验的临床应用[J].中华心血管病杂志,2006,34(4):381-384. 被引量:104
  • 2中华医学会心血管病学分会 中华心血管病杂志编辑委员会.肺动脉高压筛查诊断与治疗专家共识[J].中华心血管病杂志,2007,35:979-987.
  • 3Weitzenblum E. Chronic cor pulmonale. Heart, 2003, 89:225- 230.
  • 4Voelkel NF, Quaife RA, Leinwand LA, et al. Right ventrieular function and failure: report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure. Circulation, 2006, 114 : 1883-1891.
  • 5Calvani M, Reda E, Arrigoni-Martelli E. Regulation by carnitine of myocardial fatty acid and carbohydrate metabolism under normal and pathological conditions. Basic Res Cardiol, 2000, 95:75-83.
  • 6Loster H, Miehe K, Punzel M, et al. Prolonged oral L-carnitine substitution increases bicycle ergometer performance in patients with severe, ischemically induced cardiac insufficiency. Cardiovasc Drugs Ther, 1999, 13 : 537-546.
  • 7Evans AM, Fornasini G. Pharmacokinetics of L-carnitine. Clin Pharmacokinet, 2003, 42 : 11 : 941-967.
  • 8Schaper J, Elsasser A, Kostin S. The role of cell death in heart failure. Circ Res, 1999, 85: 867-869.
  • 9Baker H, DeAngelis B, Orlando J, et al. Cardiac carnitine leakage is promoted by cardiomyopathy. Nutrition, 2005, 21: 348 -350.
  • 10Vescovo G, Ravara B, Gobbo V, et al. L-Carnitine : a potential treatment for blocking apoptosis and preventing skeletal muscle myopathy in heart failure. Am J Physiol Cell Physiol, 2002, 283 : C802-C810.

共引文献14

同被引文献358

引证文献32

二级引证文献240

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部